

REFERENCES

- Allen, HB.; Honig, PJ. and Leyden, JJ. (1982):
Selenium sulphide: Adjunctive therapy for tinea capitis. Pediatrics; 69: 81-83.
- Amer, M.; Taha, M.; Tosson, Z. and El-Garf (1981):
Causative dermatophytes in Egypt. International Journal of Dermatology, 20 (6): 431-434.
- Anderson, DW. (1965):
Griseofulvin; Biology and clinical usefulness. Ann. Allerg, 23: 103-110.
- Berney, D. and Shuck, K. (1978):
Heterocyclic spino-naphthalenones. Part I: Synthesis and reactions of some spino (ClH-naphthalenone) -1,3-piperidines. Helv. Chim. Acta; 61: 1262-73.
- Blank, H.; Roth, FJ. JR. and Smith, JGJR, (1959):
The treatment of dermatomycosis with orally administered griseofulvin. Arch. Dermatol., 79: 259-266.
- Blank, H. (1982):
Commentary: Treatment of dermatomycoses with griseofulvin. Arch Dermatol., 118: 835-836.
- Borgers and Van Custem, J. (1985):
Ketoconazole induced morphological changes in yeasts and dermatophytes. In Meinhof W (ED), Oral therapy in dermatomycoses: a step forward, PP. 51-60, The medicine publishing foundation, Oxford.
- Borgers, M. and Van De Ven, M.A. (1987):
Degenerative changes in fungi after itraconazole treatment. Rev. Inf. Dis., 9: 533-546.

Botter, AA. and Nuigen, STM. (1981):

Further experiences with ketoconazole in the treatment of onychomycosis. *Mykosen*, 24: 156-166.

Brammer, K.W. and Lars, L.J. (1987):

Single dose oral fluconazole in the treatment of vulvovaginitis: An interim analysis of clotrimazole tablets. Recent trends in the Discovery, Development and Evaluation of Antifungal Agents. R.A. Fromthing (E.d), J.R. Prouse publisher, S.A.

Brian, PW.; Curtis, PJ. and Hemming, HG. (1946):

A substance causing abnormal development of fungal hyphae produced by *penicillium janzewskii*: I. Biological assay, production and isolation of curing factor. *Trans Br. Mycol. Soc.*, 29: 173-187.

Brian, P.W. (1960):

Control of fungal diseases of plants with griseofulvin. *Trans St. John's Hosp. Dermatol. Soc.*, 45:4-6.

Cauwenbergh, G. and De Donker, P. (1987):

The clinical use of itraconazole in superficial and deep mycoses. Itraconazole scientific monograph. Beerse, Belgium: Janssen Pharmaceutica, 113-24.

Cauwenbergh, G.; Heykants, J. and Woesten, Borghs, R. (1988):

Pharmacokinetic profile of orally administered itraconazole in human skin. *J. Am. Acad. Dermatol.* 18: 263-8.

Cauwenberg, G.; Degreef, H. and Hey, Kants, J. (1988):

Pharmacokinetic profile of orally administered itraconazole in human skin. *J. Am. Acad. Dermatol.*, 19: 263.

Cohen, J. (1982):

Antifungal chemotherapy, *Lancet*, 2: 532-537.

Cox, FW.; Stiller, RL. and South, DA. (1981):

Oral ketoconazole for dermatophyte infections.
J. Am. Acad. Dermatol., 6: 455-463.

Crounse, RG. (1961):

Human pharmacology of griseofulvin: The effect of fat intake on gastrointestinal absorption. J. Invest. Dermatol, 529-532.

Crutcher, N.; Rosenberg, EW. and Belew, PW. (1989):

Oral nystatin in the treatment of acne vulgaris (Letter). J. Am. Acad. Dermatol, 20: 861.

Cullen, SL. and Catalano, PM. (1967):

Griseofulvin-warfarine antagonism.
JAMA, 199: 582-583.

Daneshmand, T.K. and Warnock, D.W. (1988):

Clinical pharmacokinetics of ketoconazole.
Clin. Pharmacokinet, 14: 13-34.

Davies, RP.; Everdall, JD. and Hamilton, E. (1967):

Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. Br. Med. J., 3: 464-468.

Delescluse, J.; Cauwenbergh, G. and Degreef, H. (1986):

Itraconazole, a new orally active antifungal in the treatment of pityriasis versicolor.
Br. J. Dermatol, 14: 701-3.

Dudley, MN. (1990):

Clinical pharmacology of fluconazole, pharmacotherapy 10, No. 6, Part 3: 1415-1455.

Dupont, B. and Drouliet, E. (1987):

Early experience with fluconazole in vitro and in patients: Pharmacokinetic studies and clinical results. Rev. Infect. Dis., 9: 571-576.

Duschinsky, R.; Plevan, E. and Heide Lberger, C. (1957):

The synthesis of 5-fluoro-pyrimidines. J. Am. Chem. Soc., 79: 4559-4560.

El Mazny, HR.; Abdel-Fattah, A. and Abdallah, MA. (1972):

Study of tinea cruris in Egypt, Mykosen, 15: 331.

Epstein, WL.; Shah, VP. and Rigelman, S. (1972):

Griseofulvin levels in Stratum corneum; Study after oral administration in man. Arch. Dermatol, 106, 344-348.

Freingold, D.S.; Taplin, D. and Freed, Berg, I.M. (1979):

Infections, J. Invest. Dermatol, 73: 452-9.

Ford, GP.; Ive, FA. and Midgley, G. (1982):

Pityrosporum folliculitis and ketoconazole. Br. J. Dermatol, 707: 691-695.

Ford, GP.; Farr, PM. and Shuster, S. (1984):

The response of seborrheic dermatitis to ketoconazole. Br. J. Dermatol, 111: 603-607.

Foulid, G.; Wajsz Cruik, C.; Weidler, DJ.; Gary, DJ. and Gipson, P. (1988):

Steady state parenteral kinetics of fluconazole in man Ann. NY. Acad. Sc., 544: 427-30.

Geogoporilos, A.; Petranyi, G. and Mieth, H. (1981):

In vitro activity of naftifine, a new antifungal agent. Antimicrob agents Chemother, 19: 386-9.

Gordard, M.; Buffard, Y. and Ferrari, H. (1986):

Spectra d'action in vitro d'un Norwel anti fongique derive de la naftifine; la terbinafine (SF 86-327) Pathol. Biol. (Paris), 34: 680-3.

Gray Bill, JR. and Craven, PC. (1983):

Antifungal agents used in systemic mycoses; activity and therapeutic use. *Drugs*, 25: 41-62.

Gray bill, JR.; Galginai, J.; Stevens, D.; Dismukes, W. and Claud, G. (1986):

Progress in treatment of systemic mycoses: recent trials of the mycoses study group. In I Watu K, Van den bossche H. (Eds). *In vitro and in vivo evaluation of antifungal agents*, Elsevier Science Publishers.

Granier, F.; Kanitakis, J. and Hermier, C. (1987):

Antifungal chemotherapy. *J. Am. Acad. Dermatol*, 16: 243-9.

Greenberg, JR. (1979):

Griseofulvin resistance. *Int. J. Dermatol*, 18: 701.

Grave, JF.; Macmillan, J.; Mulholl, TPC. and Rogers, M. (1952):

Griseofulvin part IV structure. *J. Chem. Soc. P.* 3977-3987 (Cited in Brian PW + Ref No., 110).

Gupta, AK.; Brown, MD. and Ellis, CN. (1989):

Cyclosporine in Dermatology. *J. Am. Acad. Dermatol*, 21: 1245-1256.

Hamilton-Miller, JM. (1974):

Fungal sterols and the mode of action of the polyene antibiotics. *Adv. Appl. Microbiol.*, 17: 109-134.

Haneke, E. (1987):

Fluconazole skin levels during and after treatment. In: *Abstracts of the IVth Annual Symposium of the skin pharmacology Society. Cologne.*

Hanger, DP.; Jevens, S. and Shaw, JTB. (1988):

Fluconazole and testosterone: in vivo and in vitro studies. Antimicrob agents Chemother 32: 464-8.

Hans, F.; Merk, MD. and Hassan Mukhtar, PHD. (1989):

Azole antifungals. Clin in Dermatol. 7: 122-124.

Hay, RJ. (1990):

Itraconazole in the management of chronic dermatophytosis. J. Am. Dermatol, 23: 561-4.

Heel, RC.; Brogden, RN.; Cormine, A.; Morley, PA. and Speight, TM. (1982):

Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs, 23: 1-36.

Heel, RC. (1988):

Dermatomycoses. In: Levine HB (ed.) Itraconazole in the management of fungal disease. Auckland, New Zealand: AD.S Press, 85-7.

Heers, J.; Backs, LJ. and Van Custem, J. (1984):

Antimycotic azoles. Part 7, synthesis and antimycotic properties of R51211 and its congeners. J. Med.Chem., 27: 894-900.

Henderson, J.T. (1987):

Fluconazole. A significant advance in the management of human fungal disease. Recent trends in the discovery, development and evaluation of Antifungal Agents. R.A. Fromthing (Ed.), J.R Prous Science Publishers, S.A.

Heykants, J.; Michaels, M. and Meuldermans, W. (1987):

The pharmacokinetics of itraconazole in animals and in man. An overview. In Fromling RA (ed): Recent trends in the discovery, development and evaluation of Antifungal agents. Barcelona: Prous Science Publishers. SA, 57-83.

Holt, RJ. (1980):

The imidazoles. In: Speller D.C.E. (ed). Antifungal chemotherapy. Chichester: John Wiley, 107-47.

Horsburg, CR. and Kirkpatrick, CH. (1983):

Ketoconazole and the liver. Lancet, 1: 860.

Humphrey, MJ.; Jevans, S. and Torbit, MH. (1985):

Pharmacokinetic evaluation of UK 49858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother, 28: 648-53.

Janssen, PAJ. and Symoens, JE. (1983):

Hepatic reactions during ketoconazole treatment. Am. J. Med., 74 (1B): 80-85.

Jevans, S.; Lees, L. and Tarbit, M. (1985):

Early clinical experience with UK-49, 858 in human volunteers and patients. 14th ICC, Abstract, Kyoto, June, 14: 110-3.

Jones, HE. (1982):

Therapy of superficial fungal infections. Med. Clin. North. Am., 66: 873-893.

Jones, HE. (1984):

Ketoconazole. In Fleisch major R (Ed.) Progress in diseases of the skin. Grune Stratton, New York, 2: 217-249.

Kerridge, D. and Whelan, WL. (1984):

Mode of action of antifungal agents (Trinci APJ and Riley J.R. (eds). British Mycology Society, London, 343-375.

Larry, E.; Millikan, M.D.; Joseph, P. and Shrum, M.D.
(1991):

Antifungal agents. Systemic Drugs for skin diseases
PP. 25-42.

Lazar, JD. and Wiliner, KD. (1989):

Key drug interaction studies with fluconazole.
Presented at the symposium on major developments in
the management of bacterial and fungal infections,
Vancouver, Canada, August 19-23.

Leshner, JL. Jr. and Smith, JG. Jr. (1987):

Antifungal agents in dermatology. J. Am. Acad.
Dermatol., 17: 383-394.

Lewis, JH.; Zimmerman, HJ.; Benson, G. and Ishak, KG.
(1984):

Hepatic injury associated with ketonazole therapy.
Gastroenterology, 86: 503-510.

Lyell, A. (1967):

A review of toxic epidermal necrolysis in Britian.
Br. J. Dermatol, 79: 662-671.

Lynch, PJ.; Minkin, W. and Smith, EB. (1969):

Ecology of Candida albicans in candidiasis of the
groin. Arch Dermatol, 99: 154-160.

Marriot, MS.; Andrews, RT.; Richardson, K. and Troke, PF.
(1985):

The antifungal activity of UK-49, 858 in animal
models of superficial infections. In: Recent
advances in Chemotherapy. University of Tokyo Press,
3: 1936-1937.

Massa, MC. and Rogers, RS. (1981):

Griseofulvin therapy of lichen planus. Acta Derm
Venereol (Stockh), 61: 547-550.

Mauceri, AA.; Cullen, SI.; Vandeveld, AG. et al. (1974):

Flucytosine: An effective oral treatment for chromomycoses. Arch Dermatol, 109: 873-876.

Medoff, G. and Kobayashi, GS. (1980):

Strategies in the treatment of systemic fungal infections. N. Engl. J. Med., 302: 145-155.

Medoff, G.; Kobayashi, GA. and Speller, DCE. (1980):

Antifungal chemotherapy. John Wiley and Sons (ed): Chichester, PP. 3-33.

Meinhof, W.; Girardi, RM. and Stracke, A. (1984):

Patient non-compliance in dermatomycosis: Results of a survey among dermatologists and general practitioners and patients. Dermatologica :169 (Suppl): 57-66.

Michael, SS. and William, ED. (1988):

Azole antifungal agents: Emphasis on new triazole. Antimicrobial agents and chemotherapy. American Society of microbiology, Jan, Vol. 32, No. 1-8.

Millikan, S.; Henlenglass, G. and Powles, R. (1988):

Fluconazole pharmacokinetics following oral dosage in leukaemic patients receiving analogous bone marrow transplantation. Bone Marrow Transplant, 3: 324-5.

Naeyaert, JM.; Bersaques, J.; Cuyper, C.; Hindrycks, PH.; Landuyt, H. and Gords, B. (1987):

Fluconazole (UK, 49, 858), A novel Oral antifungal in the treatment of fungal skin infections. Results of an open study in 43 patients. Recent trends in discovery, development and evaluation of Antifungal Agents. R.A. Fromthing (Ed) J.R. Prous Science Publishers, S.A.

Nauceri, AA. (1989):

Antifungal agents in Dermatology. Clinical and Experimental Dermatology. Blackwell Scientific Publications. Vol. 14, No. 2.

Odds, FC.; Abott, A.B.; Pye, GW. and Troke, PF. (1986):

Improved method for estimation of azole antifungal inhibitory concentrations against *Candida* species, based on azole/antibiotic interactions. J. Med. Vet. Mycol. 24: 305-311.

Paget, GE. and Walpole, AL. (1988):

Treatment of fungal skin infections: State of Art. J. Am. Acad. Dermatol, 13: 549-51.

Petranyi, G.; Meingassner, JG. and Mieth, H. (1987):

Antifungal activity of allylamine derivative, terbinafine in vitro. Antimicrob Agents Chemother, 31: 1365-8.

Petranyi, G.; Meingassner, JG. and Mieth, H. (1989):

Activity of Terbinafine in experimental fungal infections in laboratory animals. Antimicrob Agents Chemother, 31: 1558-61.

Pont, A.; Williams, PL. and Azhar, S. (1982):

Ketoconazole blocks adrenal steroid and testosterone synthesis. Ann. Intern. Med., 97: 370-372.

Richardson, K.; Brammer, JW.; Marriott, MS. and Troke, PF. (1985):

Activity of UK-49, 858, a bis-triazole derivative against experimental infections with *Candida albicans* and *Trichophyton mentagrophytes*. Antimicrob Agents Chemother, 27: 832-835.

Richardson, K. (1983):

U.S. patent 4, 404, 216. Quoted from: Michael S.M. and Richardson K. (1987): The discovery and mode of action fluconazole. Recent trends in the discovery, development and evaluation of antifungal agents. R.A. Fromthing (ed). JR. Prous Science Publishers, S.A.

Riegelman, S.; Rowland, M. and Epstein, WL. (1970):

Griseofulvin phenobarbital interaction in man. JAMA, 213: 426-431.

Rippon, JW. (1986):

A new era in antimycotic agents (ed). Arch Dermatol, 122: 399-402.

Roberts, DT. (1982):

The current status of systemic antifungal agents. Br. J. Dermatol, 106: 597-602.

Robertson, MH.; Rich, P.; Parkorf, L. and Hanfin, JM. (1982):

Ketoconazole in griseofulvin resistant dermatophytosis. Archives of Dermatology, 6: 224-229.

Roseauw, D.; Willemsen, M. and Kint, R. (1990):

Itraconazole in the treatment of superficial mycoses: a double-blind study versus placebo. Clin. Exp. Dermatol., 101-4.

Rosenblat, HM.; Bryne, W.; Ament, ME.; Graybill, J. and Stiehm, ER. (1982):

Successful treatment of mucocutaneous candidiasis with ketoconazole. Journal of Paediatrics, 97:657-660.

Rosenthal, SA. and Wise, RS. (1960):

Studies concerning the development of resistance to griseofulvin by dermatophytes. Ibid., 684. ←

Ryder, NS. and Dupont, MC. (1985):

Inhibition of squalene epoxidase by allyamine antimycotic compounds: a comparative study of fungal and mammalian enzymes. Biochem. J., 230: 765-70.

Ryder, NS. (1989):

The mechanism of action of terbinafine. Clin. Exp. Dermatol, 14: 98-100.

Saag, MS. and Dismukes, WE. (1988):

Azole antifungals: Emphasis on new triazole.
Antimicrob Agents Chemother, 32: 1-8.

Sande, MA. and Mandell, GL. (1985):

Antimicrobial agents, antifungal and antiviral agents. In: Goodman Gilman A, Goodman LS, Rall TW, et al. (eds). The pharmacological basis of therapeutics. New York : Macmillan. 1217-1239.

Savin, RC. (1984):

Systemic ketoconazole in tinea versicolor: a double-blind evaluation of 1-year follow up. J. Am. Acad. Dermatol, 10: 824-830.

Schuster, I. (1985):

The interaction of representative members from two classes of antimycotics-the azoles and the allylamines with cytochrome P-450 in steroidogenic tissues and liver. Xenobiotica, 15: 529-46.

Schuster, I. (1987):

Potential of allylamines to inhibit cytochrome P-450. In: Fromthing RA (ed). Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona; Barcelona; JR Prous, 471-7.

Sehgal, VN.; Bikhehandani, R. and Koranne, RV. (1980):

Histopathologic evaluation of griseofulvin therapy in lichen planus: A double blind controlled study. Dermatologica. 61: 22-27.

Shadomy, S.; Espinel-Lugroff, A. and Gebhart, RJ. (1985):

In vitro studies with SF 86-327 a new orally active allylamine derivative. J. Med. Vet. Mycol., 23: 125-32.

Smith, KJ.; Warnock, D.; Kennedy, CTC.; Hohnson, EM.; Hopwood, V.; Van Custem, J. and Vanden Bosche, H. (1986):

Azole resistance in candida albicans, J. Med. Vet. Mycol., 24: 133-144.

Stephen, A.; Gzok, P. and Mole, D. (1987):

Terbinafine: initial clinical results. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona. JR. Prous, 511-20.

Stern, JJ.; Hartman, BJ.; Sharkey, P.; Rawland, V.; Squires, KE.; Murray, HW. and Graybill, JR. (1988):

Oral fluconazole therapy for patients with acquired immunodeficiency syndrome. Am. J. Med., 29: 178-179.

Stutz, A. (1987):

Allylamine derivatives a new class of active substances in antifungal chemotherapy. Angew chemie International Edition England, 26: 320-8.

Stutz, A. (1988):

Synthesis and structure activity correlations with allylamine antimycotics. Ann. NY Acad. Sci., 544: 46-62.

Suchil Centro, P.; Montero-Gei, FL.; Robles, M.; Perera Ramirez, A.; Welsh, O. and Male, O. (1991):

Oral fluconazole 150 mg once weekly in treatment of tinea corporis, cruris. In: Fluconazole: Abstracts from the world literature, Vol. 11, ADIS. International Inc., Langhorne, PA.

Symoens, J. and Cauwenbergh, G. (1983):

Ketoconazole, a new step in the management of fungal disease. In Jucker E. (ed). Progress in drug research, Vol. 27, PP. 38-84, Birkhauser Verlag, Basel.

Tachibana, M.; Noguchi, Y. and Monro, AM. (1987):

Toxicology of fluconazole. Recent trends in discovery, development and evaluation of antifungal agents. RA. Fromthing (Ed), JR Prous, Science Publishers, S.A.

Torok, I.; Simon, G. and Pap, M. (1982):

An evaluation of two years of clinical experience with ketoconazole. Mykosen, 25: 136-142.

Troke, P.F.; Andrews, R.T.; Brammer, K.W.; Marriot, M.S. and Richardson, K. (1985):

Efficacy of UK 49, 858 (Fluconazole) against candida albicans experimental infections in mice. Antimicrob Agents Chemother, 28: 815-818.

Troke, P.F. (1987):

Efficacy of fluconazole in animal models of superficial and opportunistic systemic fungal infections. Recent trends in the discovery, development and evaluation of antifungal agents (E.D), JR. Prous Science Publishers, S.A.

Van Custem, J.; Van Gerven, F.; Van den Ven, M.A.; Borgers, M. and Janssen, P.A.J. (1984):

Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother, 26: 527-534.

Van Custem, J. and Janssen, P.A.J. (1985):

Antifungal activity of new azoles, recent advances in chemotherapy antimicrobial (Section 3). In Ishigume J. (ed): Proceedings of the 14th International Congress of Chemotherapy Kyoto. Tokyo: University of Tokyo Press, 1942-1943.

Van Custem, J.; Van Gerven, F. and Janssen, P.A.J. (1987):

The in vitro and in vivo antifungal activity of itraconazole. Recent trends in the discovery, development and evaluation of antifungal agents. RA Fromthing (Ed) JR, Prous Science Publishers, S.A.

Vanden Bossche, H.; Willemsens, G.; Cools, W.; Marichal, P. and Lauwers, W. (1983):

Hypothesis on the molecular basis of the antifungal activation of N-substituted imidazoles and triazoles. Biochem. Soc. Trans. 11: 665-667.

Vanden Bossche, H.; Bellens, W.; Cools, J.; Gorrens, P.; Marichal, H.; Verhoeven, G.; Willemsens, R.; De Coster, W.; Lawers and Le Jeune (1986):

Cytochrome P-450: Target for Itraconazole. Drug Dev Res. 8: 298.

Vanden Bossche, H.; Willemsens, G. and Marichal, P. (1987):

Anticandida drugs-the biochemical basis for their activity. CRC Crit Rev. Microbiol. 15: 57-72.

Vanden Velde, AG.; Mauceri, AA. and Johnson, JE. (1972):

5-fluorocytosine in the treatment of mycotic infections. Ann. Intern. Med., 77: 43-51.

Van Dyke, CPH. and Weber, JCP. (1984):

Interaction between oral contraceptives and griseofulvin. Br. Med. J. 288: 1125-1126.

Villars, V. and Jones, TC. (1990):

Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycosis of skin and nails. J. Dermatol, Treat. 1 (Suppl 2): 33-8.

Wilson, JW. (1955):

In: Text Book of Therapy of fungus diseases. Edited by Sterberg T.H and Newcomer V.D Little, Brown and Co. Boston; P. 27.

Zaias, N. and Drachman, D. (1983):

A method for the determination of drug effectiveness: Trials with ketoconazole and griseofulvin microsize. J. Am. Acad. Dermatol, 9: 912-919.

Zaias, N. and Serrano, L. (1989):

The successful treatment of finger trichophyton rubrum onychomycosis with oral terbinafine. Clin. Exp. Dermatol, 14: 120-3.